ES2662611T3 - Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV - Google Patents

Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV Download PDF

Info

Publication number
ES2662611T3
ES2662611T3 ES15706804.0T ES15706804T ES2662611T3 ES 2662611 T3 ES2662611 T3 ES 2662611T3 ES 15706804 T ES15706804 T ES 15706804T ES 2662611 T3 ES2662611 T3 ES 2662611T3
Authority
ES
Spain
Prior art keywords
htlv
antigen
ctd
protein
fkpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15706804.0T
Other languages
English (en)
Spanish (es)
Inventor
Elke Faatz
Peter Muench
Christian Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2662611T3 publication Critical patent/ES2662611T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES15706804.0T 2014-02-28 2015-02-26 Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV Active ES2662611T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157165 2014-02-28
EP14157165.3A EP2913338A1 (en) 2014-02-28 2014-02-28 Soluable and immunoreactive variants of HTLV capsid antigen p24
PCT/EP2015/053966 WO2015128394A2 (en) 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24

Publications (1)

Publication Number Publication Date
ES2662611T3 true ES2662611T3 (es) 2018-04-09

Family

ID=50184798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15706804.0T Active ES2662611T3 (es) 2014-02-28 2015-02-26 Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV

Country Status (7)

Country Link
US (2) US10466242B2 (enExample)
EP (2) EP2913338A1 (enExample)
JP (1) JP6491228B2 (enExample)
CN (1) CN106029687B (enExample)
CA (1) CA2938712C (enExample)
ES (1) ES2662611T3 (enExample)
WO (1) WO2015128394A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7065781B2 (ja) * 2016-03-07 2022-05-12 エフ．ホフマン－ラ ロシュ アーゲー 抗ｐ５３抗体の検出
WO2019164402A1 (en) * 2018-02-26 2019-08-29 Technische Universiteit Eindhoven Bioluminescent biosensor for detecting and quantifying biomolecules
JP2023522278A (ja) * 2020-04-23 2023-05-29 エフ． ホフマン－ラ ロシュ アーゲー 抗体－免疫アッセイでの使用のためのコロナヌクレオカプシド抗原

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
NZ238855A (en) 1990-07-18 1994-03-25 Iaf Biochem Int Peptides, mixtures thereof and compositions useful for detecting htlv-i and htlv-ii infections
CA2117378C (en) * 1992-02-24 2003-04-15 Steven K. H. Foung Htlv-i/htlv-ii assay and method
WO1996039630A1 (en) * 1995-06-05 1996-12-12 Abbott Laboratories Detection of htlv antibodies utilizing recombinant proteins
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
JP2000078973A (ja) * 1998-09-03 2000-03-21 Tonen Corp Ｈｔｌｖ−ｉ組換え抗原
HUP0202512A2 (hu) * 1999-08-09 2002-11-28 Tripep Ab Fehérjék polimerizációját gátló anyagok és eljárások ezek alkalmazására
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
PL218245B1 (pl) 2001-06-22 2014-10-31 Hoffmann La Roche Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową i izomerazę peptydyloprolilową oraz kompozycja reagentów obejmująca ten kompleks
PL2112158T3 (pl) 2007-04-20 2012-03-30 Hoffmann La Roche Wykrywanie pierwotnych infekcji wywołanych patogenami
EP2127678A1 (en) * 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA as a tool for recombinant protein and enzyme technology

Also Published As

Publication number Publication date
JP2017512200A (ja) 2017-05-18
EP3110831A2 (en) 2017-01-04
JP6491228B2 (ja) 2019-03-27
CA2938712C (en) 2018-10-23
US10466242B2 (en) 2019-11-05
CN106029687B (zh) 2020-07-31
WO2015128394A3 (en) 2015-11-05
WO2015128394A2 (en) 2015-09-03
US11567079B2 (en) 2023-01-31
CN106029687A (zh) 2016-10-12
EP2913338A1 (en) 2015-09-02
EP3110831B1 (en) 2018-01-10
CA2938712A1 (en) 2015-09-03
US20200033342A1 (en) 2020-01-30
US20170184591A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
ES2339709T3 (es) Anticuerpo monoclonal anti-nucleo de vhc.
ES2409631T3 (es) Métodos para la detección simultánea de antígenos del VHC y anticuerpos para el VHC
ES2662611T3 (es) Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV
US20120208176A1 (en) Multivalent Epitope in Complex with a Detection Marker for the Early Serodiagnosis of Infections
ES2981438T3 (es) Novedosos antígenos proteicos de la envoltura del virus de la inmunodeficiencia humana expresados en mamíferos
WO2023060210A9 (en) Molecules, and related assays, test kits and methods
KR950701684A (ko) 뎅그열 바이러스 혈청형 1(싱가폴균주)의 cDNA서열(cDNA sequence of dengue virus serotype 1(Singapore strain))
ES2774497T3 (es) Procedimiento para la detección de un anticuerpo IgM específico para un flavivirus en una muestra
US7074555B2 (en) Detection of West Nile Virus
US7201903B2 (en) Method and device for detecting feline immunodeficiency virus
AU652919B2 (en) Cysteine thiol-protected peptides for use in immunoassays
CN114478716B (zh) 一种多肽组合及其在新型冠状病毒抗体检测中的应用
ES2623891T3 (es) Variantes de la lipoproteína 15 (Lp15) de Vibrio cholerae como aditivo anti-interferencia en inmunoensayos basados en TpN17 para la detección de anticuerpos anti-Treponema
EP3147294B1 (en) Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
US7291338B2 (en) Method and device for detecting feline immunodeficiency virus
Verma et al. A bio-safe multiple antigenic peptide (MAP) enzyme-linked immunoassay for the detection of antibodies to infectious bronchitis virus in chickens
BJ Reddy et al. Expression, purification and evaluation of diagnostic potential and immunogenicity of dengue virus type 3 domain III protein
ES2356383T3 (es) Expresión recombinante de variantes de proteína de cubierta de rubeola e1 como proteínas de fusión chaperonas, y utilización de las mismas en la detección de anticuerpos anti-rubeola.
HK1229824B (zh) Htlv衣壳抗原p24的可溶性和免疫反应性变体
HK1229824A1 (en) Soluble and immunoreactive variants of htlv capsid antigen p24
JPH02218693A (ja) 新規ペプチド
AU614971B2 (en) Hiv polypeptide, its preparation and use in detection of hiv antibodies
Praveena et al. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
Flaviviruses et al. Use of Recombinant E Protein Domain